[1]孙晓红,刘东敏△.益气强心汤对射血分数中间范围型冠心病心力衰竭患者心脏重塑和生活质量的影响*[J].陕西中医,2020,(10):1392-1395.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.014]
　SUN Xiaohong,LIU Dongmin..Effect of Yiqi Qiangxin decoction on cardiac remodeling and quality of life in patients with heart failure with mid-range ejection fraction[J].,2020,(10):1392-1395.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.014]
点击复制

益气强心汤对射血分数中间范围型冠心病心力衰竭患者心脏重塑和生活质量的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年10期
页码:
1392-1395
栏目:
临床研究
出版日期:
2020-10-05

文章信息/Info

Title:
Effect of Yiqi Qiangxin decoction on cardiac remodeling and quality of life in patients with heart failure with mid-range ejection fraction
作者:
孙晓红1; 刘东敏2△
1.陕西中医药大学附属医院(咸阳 712000); 2.陕西中医药大学第一临床医学院(咸阳 712046)
Author(s):
SUN Xiaohong; LIU Dongmin.
The Affiliated Hospital of Shaanxi University of Chinese Medicine(Xianyang 712000)
关键词:
益气强心汤;  冠心病;  射血分数中间范围型心力衰竭;  心脏重塑;  生活质量
Keywords:
Yiqi Qiangxin decoction;  Coronary heart disease;  Heart failure with mid-range ejection fraction;  Heart remodeling;  Quality of life
分类号:
R541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.10.014
文献标志码:
A
摘要:
目的:观察益气强心汤对射血分数中间范围型冠心病心力衰竭患者心脏重塑和生活质量的影响。方法:将96例射血分数中间范围型冠心病心力衰竭患者按照随机数字表分为对照组和观察组,每组各48例,对照组采用常规标准化抗心力衰竭治疗,观察组在对照组基础上加用益气强心汤治疗,疗程12周。记录两组临床疗效,并比较两组治疗前后中医症候积分、心功能分级和运动耐量,心脏超声指标和生活质量的变化。结果:观察组治疗总有效率明显高于对照组(P<0.05)。与治疗前比较,两组治疗后中医症候积分、NYHA心功能分级均明显降低(P<0.05),6 min步行试验(6MWT)距离增加(P<0.05),与对照组治疗后比较,观察组以上指标均优于对照组(P<0.05)。与治疗前比较,两组左心室射血分数(LVEF)二尖瓣舒张早期最大速度/新房收缩期之最大速度(E/A)明显增加(P<0.05),左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、血清N末端B型利钠肽原(NT-proBNP)明显降低(P<0.05),与对照组治疗后比较,观察组以上指标均优于对照组(P<0.05)。与治疗前比较,两组MLHFQ量表各维度中体力限制、躯体状况、情绪变化、社会限制评分和总评分均明显降低(P<0.05),与对照组治疗后比较,观察组以上评分均低于对照组(P<0.05)。结论:益气强心汤可显著改善此类患者心功能和运动耐量,抑制或逆转心脏重塑,有利于生活质量的改善。
Abstract:
Objective:To observe the effect of Yiqi Qiangxin decoction combined with atorvastatin calcium on cardiac remodeling and quality of life in patients with heart failure(HFmrEF).Methods:96 HFmrEF patients were divided into control group and observation group according to the random number table,48 cases in each group.The two groups were treated with routine standardized anti heart failure treatment.The control group was treated with atorvastatin calcium on its basis,and the observation group was treated with Yiqi Qiangxin decoction on the basis of the control group for 12 weeks.The clinical effects of the two groups were recorded,and the changes of TCM symptom score,cardiac function grade,exercise tolerance,cardiac ultrasound index and quality of life before and after treatment were compared.Results:The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).Compared with before treatment,the score of TCM symptoms and NYHA heart function grade in the two groups were significantly reduced(P<0.05),and the distance of 6MWT was increased(P<0.05).Compared with the control group,the above indexes in the observation group were better than those in the control group(P<0.05).Compared with the control group,the left ventricular ejection fraction(LVEF),E/A increased significantly(P<0.05),the left ventricular end diastolic diameter(LVEDD),left ventricular end-systolic dimension(LVESD),serum N-terminal B-type natriuretic peptide(NT-proBNP)decreased significantly(P<0.05).Compared with the control group,the above indexes of the observation group were better than those of the control group(P<0.05).Compared with before treatment,the scores of physical limitation,physical condition,emotional change,social limitation and total score of mlhfq in the two groups decreased significantly(P<0.05).Compared with the control group after treatment,the above scores in the observation group were lower than those in the control group(P<0.05).Conclusion:Yiqi Qiangxin decoction combined with atorvastatin calcium can significantly improve the cardiac function and exercise tolerance of HFmrEF patients,inhibit or reverse cardiac remodeling,and improve the quality of life.

参考文献/References:

[1] 陈怡粤,余小平,陈胜华.心力衰竭超声指数评价射血分数中间范围型心力衰竭的临床价值[J].中国老年学杂志,2018,38(10):2342-2344.
[2] 莫小凤,方理刚.射血分数中间值心力衰竭[J].中国心血管杂志,2017,22(6):457-459.
[3] Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)developed with the special contribution of the Heart Failure Association(HFA)of the ESC [J].Eur Heart J,2016,37(27):2129-2200.
[4] 国家食品药品监督管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:79-80.
[5] 李长青,冯玉宝,苏 平.6 min步行试验对于心力衰竭患者的意义[J].心血管康复医学杂志,2018,27(1):101-103.
[6] 王贤良,刘洪伟,毛静远,等.基于中国文化改良明尼苏达心力衰竭生存质量量表的测评[J].中国中西医结合杂志,2016,36(9):1072-1075.
[7] 袁小媚,孔 洪,王文艳.老年射血分数中间值心力衰竭患者的临床特点分析[J].中华老年心脑血管病杂志,2017,19(9):957-960.
[8] 周浩斌,安冬琪,詹 琼,等.不同射血分数心力衰竭患者临床特征和预后的回顾性分析[J].中华内科杂志,2017,56(4):253-257.
[9] 郁 鹏,房加雄,姬 乐,等.心力衰竭患者血清肌钙蛋白浓度与心脏重塑及心肝肾功能的关系及意义[J].临床医学,2016,36(7):1-4.
[10] 陈建淑,姚亚丽,陈凤梅,等.基于NT-proBNP的灰值区射血分数中间值心力衰竭的研究[J].临床心血管病杂志,2018,34(8):769-772.
[11] 姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志,2016,45(8):1064-1065.
[12] 陈武君,庄洪标,黄火剑,等.益气活血化瘀方联合西药对冠心病心衰介入术后左心室功能及生活质量影响的研究[J].陕西中医,2017,38(11):1517-1518.
[13] 向宗兴,拓 文,仇卫峰,等.黄芪保心汤配合西药治疗慢性心力衰竭临床研究[J].陕西中医,2019,40(8):1085-1087,1097.
[14] 鲜 文.重组人 BNP 联合黄芪注射液对 AMI PCI 术后心力衰竭患者心功能及血清炎症因子的影响[J].心血管康复医学杂志,2019,28(4):424-428.
[15] 刘 妍,谢铱子,张 璐,等.采用网络药理学研究黄芪-葶苈子药对治疗心力衰竭的作用机制[J].中国药房,2019,30(11):1513-1518.
[16] 彭 勇,何 江,周棉勇.黄芪汤加减治疗溃脓期肺痈临床观察[J].陕西中医,2020,41(1):66-69.

相似文献/References:

[1]吴欣芳,吴 宝,王吉元,等.升陷汤加味治疗冠心病室性早搏临床研究*[J].陕西中医,2020,(11):1563.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.012]
　WU Xinfang,WU Bao,WANG Jiyuan,et al.Effect of Shengxian decoction on ventricular premature beat of coronary heart disease[J].,2020,(10):1563.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.012]
[2]叶 玺,叶穗霖,成 莎.止消通脉清热饮治疗冠心病合并糖尿病疗效及对患者心功能和血清孤独G蛋白偶联受体配体-12水平的影响*[J].陕西中医,2020,(11):1584.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.018]
　YE Xi,YE Suilin,CHENG Sha..Effect of Zhixiao Tongmai Qingre decoction on cardiac function and serum Apelin-12 level in patients with coronary heart disease and diabetes mellitus[J].,2020,(10):1584.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.018]
[3]刘紫薇,成泽东,董宝强,等.基于“阴病治阳”理论探讨针刺治疗冠心病[J].陕西中医,2022,(12):1768.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.028]
[4]张 宸,李 景,尚菊菊.2型糖尿病合并冠状动脉硬化患者心率变异性与中医证型相关性分析[J].陕西中医,2023,(1):68.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.016]
　ZHANG Chen,LI Jing,SHANG Juju.Analysis of the correlation between heart rate variability and TCM syndromes in patients with type 2 diabetes mellitus complicated with coronary atherosclerosis[J].,2023,(10):68.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.016]
[5]王 虎,张依轮,姜德友.名中医姜德友基于寒地致病因机特色论治冠心病经验[J].陕西中医,2024,(1):111.[doi:DOI:10.3969/j.issn.1000-7369.2024.01.026]
　WANG Hu,ZHANG Yilun,JIANG Deyou.JIANG Deyou's experience in treating coronary heart disease based on the characteristics of cold regions[J].,2024,(10):111.[doi:DOI:10.3969/j.issn.1000-7369.2024.01.026]
[6]彭华容,王 茜,廖 波,等.三七参芪汤对冠心病患者肥胖且低密度脂蛋白胆固醇未达标的干预价值研究[J].陕西中医,2024,(10):1369.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.016]
　PENG Huarong,WANG Qian,LIAO Bo,et al.Clinical observation of Sanqi Shenqi decoction in the intervention of substandard low-density lipoprotein cholesterol in obese patients with coronary heart disease[J].,2024,(10):1369.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.016]

备注/Memo

备注/Memo:
*陕西省中医药管理局课题(13-LC065)
更新日期/Last Update: 2020-10-10